Paclitaxel (PTX) is a first‐line chemotherapeutic drug for non‐small cell lung cancer (NSCLC) but it can induce indoleamine 2,3‐dioxygenase (IDO) activation, which severely lowers down its immuno‐chemotherapeutic effect. This evidence concerns the gene IDO1 and lung cancer.